Wnt5a augments intracellular free cholesterol levels and promotes castration resistance in prostate cancer.

ABSTRACT:

Background

Prostate cancer (PCa) is a leading cause of cancer-related mortality in men globally. While androgen deprivation therapy (ADT) can extend the asymptomatic phase and overall survival of patients with metastatic PCa, prolonged ADT often leads to the development of castration-resistant prostate cancer (CRPC) within 18-24 months. The mechanisms underlying CRPC remain incompletely understood, presenting a significant challenge in clinical prostate cancer treatment.

Methods

In this study, we investigated the role of Wnt5a, a member of the Wnt family, in CRPC. Tumor tissues from CRPC patients were analyzed to assess the expression levels of Wnt5a. Prostate cancer cells were used to examine the impact of Wnt5a on androgen-dependent and -independent growth, as well as sens

SUBMITTER: Guo Y 

PROVIDER: S-EPMC11921506 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature